Table 2.
Relation between clinical and radiographic parameters and VAS pain: univariate linear regression
| Variable | Inclusion | 1 year | 2 years | 5 years |
|---|---|---|---|---|
| β (95% CI) | β (95% CI) | β (95% CI) | β (95% CI) | |
| Female sex | −2.12 (−9.71, 5.46) | 1.44 (−5.63, 8.50) | 11.89 (3.95, 19.81) | 6.16 (−1.55, 13.86) |
| Age (per year) | −0.27 (−0.51, −0.04) | −0.21 (−0.43, 0.01) | −0.28 (−0.53, −0.03) | 0.04 (−0.21, 0.28) |
| Symptom duration (months) | −1.67 (−2.84, −0.50) | 0.34 (−0.77 – 1.45) | 0.18 (−1.10, 1.46) | 0.24 (−0.99, 1.46) |
| Body mass index (per kg/m2) | 0.04 (−0.97, 1.04) | - | 0.43 (−0.61, 1.47) | - |
| RF seropositivity | −1.23 (−8.36, 5.90) | 3.06 (−3.54, 9.66) | 6.65 (−0.86, 14.16) | 1.30 (−6.07, 8.63) |
| Anti-CCP seropositivity | −1.61 (−9.10, 5.89) | 5.47 (−1.67, 12.60) | 2.69 (−5.58, 10.96) | −1.64 (−9.52, 6.23) |
| SJC28 | 1.34 (0.67, 2.01) | 1.90 (1.15, 2.66) | 1.71 (1.00, 2.42) | 1.85 (1.18, 2.52) |
| TJC28 | 1.41 (0.91, 1.91) | 2.25 (1.63, 2.88) | 2.19 (1.55, 2.83) | 2.02 (1.39, 2.65) |
| ESR (per mm/h) | 0.27 (0.14, 0.40) | 0.35 (0.19, 0.51) | 0.47 (0.27, 0.67) | 0.34 (0.08, 0.60) |
| CRP (per mg/l) | 0.27 (0.17, 0.38) | 0.34 (0.16, 0.51) | 0.39 (0.15, 0.64) | 0.48 (0.25, 0.70) |
| SHS | −0.29 (−0.69, 0.10) | −0.02 (−0.26, 0.26) | 0.12 (−0.11, 0.35) | 0.05 (−0.09, 0.19) |
| ES | −0.12 (−1.39, 1.15) | 0.22 (−0.48, 0.92) | 0.44 (−0.11, 1.00) | 0.22 (−0.08, 0.53) |
| JSNS | −0.44 (−0.94, 0.06) | −0.08 (−0.39, 0.23) | 0.09 (−0.22, 0.40) | 0.01 (−0.21, 0.23) |
Bold text indicates statistical significance with p-values <0.05. VAS visual analogue scale, CI confidence interval, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide, SJC28 swollen joint count in 28 joints, TJC28 tender joint count in 28 joints, CRP C-reactive protein, ESR erythrocyte sedimentation rate, SHS Sharp-van der Heijde score, ES erosion score, JSNS joint space narrowing score